Callan Capital LLC Takes Position in Smith & Nephew SNATS, Inc. (NYSE:SNN)

Callan Capital LLC acquired a new stake in Smith & Nephew SNATS, Inc. (NYSE:SNN - Free Report) during the first quarter, according to its most recent 13F filing with the SEC. The fund acquired 9,180 shares of the medical equipment provider's stock, valued at approximately $260,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Envestnet Asset Management Inc. increased its position in shares of Smith & Nephew SNATS by 15.6% during the first quarter. Envestnet Asset Management Inc. now owns 618,691 shares of the medical equipment provider's stock valued at $17,552,000 after buying an additional 83,341 shares during the period. Hexagon Capital Partners LLC increased its position in shares of Smith & Nephew SNATS by 63.3% during the first quarter. Hexagon Capital Partners LLC now owns 1,047 shares of the medical equipment provider's stock valued at $30,000 after buying an additional 406 shares during the period. Allspring Global Investments Holdings LLC bought a new stake in shares of Smith & Nephew SNATS during the first quarter valued at about $335,000. Sequoia Financial Advisors LLC bought a new stake in shares of Smith & Nephew SNATS during the first quarter valued at about $211,000. Finally, Bessemer Group Inc. increased its position in shares of Smith & Nephew SNATS by 3,471.4% during the first quarter. Bessemer Group Inc. now owns 1,750 shares of the medical equipment provider's stock valued at $49,000 after buying an additional 1,701 shares during the period. 25.64% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several brokerages have recently weighed in on SNN. Hsbc Global Res cut Smith & Nephew SNATS from a "strong-buy" rating to a "hold" rating in a research report on Friday, April 25th. Canaccord Genuity Group upped their price target on Smith & Nephew SNATS from $27.00 to $28.00 and gave the company a "hold" rating in a research report on Thursday, May 1st. HSBC cut shares of Smith & Nephew SNATS from a "buy" rating to a "hold" rating in a research report on Friday, April 25th. Finally, UBS Group cut shares of Smith & Nephew SNATS from a "buy" rating to a "neutral" rating in a research report on Wednesday, March 12th. Six analysts have rated the stock with a hold rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Hold" and an average target price of $28.00.

Smith & Nephew SNATS Price Performance

SNN traded up $0.97 during midday trading on Wednesday, hitting $30.74. The stock had a trading volume of 3,955,612 shares, compared to its average volume of 820,430. The company has a market cap of $13.46 billion, a P/E ratio of 14.23, a price-to-earnings-growth ratio of 0.92 and a beta of 0.69. The business has a fifty day moving average of $29.19 and a 200 day moving average of $27.35. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.33 and a current ratio of 2.89. Smith & Nephew SNATS, Inc. has a 1 year low of $23.69 and a 1 year high of $31.72.

About Smith & Nephew SNATS

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.